Key facts
- ARWR - ARROWHEAD PHARMACEUTICALS, INC. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$37,882,496.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 17 Insiders of ARROWHEAD PHARMACEUTICALS, INC.
- Symbol
- ARWR on Nasdaq
- Location
- Pasadena, CA
Change
- Buy value: ; sell value: $37,882,496.
- Net share flow: -606,901.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$37,882,496.
Buys
$0
Shares: 0
Insiders: 0
Sells
$37,882,496
Shares: 606,901
Insiders: 10
Net
-$37,882,496
Shares: -606,901
Insiders: -10
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 36,065 | $0 | $2,554,519 | -$2,554,519 |
| 3-6 | 0 | 510,836 | $0 | $33,602,978 | -$33,602,978 |
| 6-9 | 0 | 50,000 | $0 | $1,525,000 | -$1,525,000 |
| 9-12 | 0 | 10,000 | $0 | $200,000 | -$200,000 |
ARROWHEAD PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher Richard Anzalone | Chief Executive Officer, Director | $251,799,942 | -$24,010,564 | -8.7% | Filing P/S | 02 Jan 2026 |
| Patrick O'Brien | Coo | $36,342,471 | -$3,123,349 | -7.9% | Mixed | 06 Jan 2026 |
| James C. Hamilton | Chief Medical Officer | $17,021,850 | -$5,651,561 | -25% | Filing P/S | 23 Apr 2026 |
| Daniel Joseph Apel | Chief Financial Officer | $11,716,127 | -$934,285 | -7.4% | Filing P/S | 22 Apr 2026 |
| Kenneth Allen Myszkowski | Chief Financial Officer | $8,967,476 | Filing P/S | 04 Jan 2025 | ||
| Javier San Martin | Chief Medical Officer | $7,417,833 | Mixed | 04 Jan 2024 | ||
| Michael S. Perry | Director | $4,977,736 | -$991,738 | -17% | Mixed | 16 Dec 2025 |
| Mauro Ferrari | Director | $4,833,710 | -$1,020,513 | -17% | Filing P/S | 26 Dec 2025 |
| Hongbo Lu | Director | $3,998,682 | -$228,334 | -5.4% | Filing P/S | 12 May 2026 |
| James Hassard | Chief Commercial Officer | $3,951,878 | Mixed | 22 Jun 2021 | ||
| William D. Waddill | Director | $3,876,262 | -$566,038 | -13% | Filing P/S | 19 Dec 2025 |
| Tracie Oliver | Chief Commercial Officer | $3,213,265 | Filing P/S | 02 Jul 2024 | ||
| Douglas B. Given | Director | $2,736,641 | Filing P/S | 16 Dec 2024 | ||
| Victoria Vakiener | Director | $2,443,095 | -$679,491 | -22% | Filing P/S | 19 Dec 2025 |
| Adeoye Y. Olukotun | Director | $2,300,928 | -$676,623 | -23% | Filing P/S | 19 Dec 2025 |
| Douglas S. Ingram | Director | $1,869,396 | Mixed | 16 Dec 2025 | ||
| Marianne de Backer | Director | $1,168,448 | Mixed | 10 Jan 2023 |
Top shareholders of ARROWHEAD PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
12%
from 13D/G
|
18,161,519
|
$1,138,727,235 | — | 31 Mar 2026 | |
| Avoro Capital Advisors LLC |
13F
13D/G
|
Company |
8.3%
from 13D/G
|
10,699,999
|
$670,889,937 | — | 31 Mar 2026 | |
| FMR LLC |
13D/G
13F
|
Company |
5.2%
|
7,349,107
|
$478,720,814 | $0 | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
|
Vanguard Portfolio Management · Company |
5.2%
|
7,269,957
|
$455,826,304 | $0 | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Vanguard Capital Management · Company |
5%
|
7,081,293
|
$443,997,071 | $0 | 31 Mar 2026 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
4.6%
from 13D/G
|
6,496,130
|
$407,307,351 | — | 31 Mar 2026 | |
| Christopher Richard Anzalone |
3/4/5
|
Chief Executive Officer, Director |
2.7%
|
3,792,739
|
$251,799,942 | -$24,010,564 | 02 Jan 2026 | |
| Patrick O'Brien |
3/4/5
|
COO |
0.39%
|
547,408
|
$36,342,471 | -$3,123,349 | 06 Jan 2026 | |
| James C. Hamilton |
3/4/5
|
Chief Medical Officer |
0.16%
|
226,958
|
$17,021,850 | -$5,651,561 | 23 Apr 2026 | |
| Daniel Joseph Apel |
3/4/5
|
Chief Financial Officer |
0.12%
|
162,905
|
$11,716,127 | -$934,285 | 22 Apr 2026 | |
| Michael S. Perry |
3/4/5
|
Director |
0.09%
|
123,059
|
$4,977,736 | -$991,738 | 16 Dec 2025 | |
| Mauro Ferrari |
3/4/5
|
Director |
0.05%
|
69,053
|
$4,833,710 | -$1,020,513 | 26 Dec 2025 | |
| William D. Waddill |
3/4/5
|
Director |
0.04%
|
56,563
|
$3,876,262 | -$566,038 | 19 Dec 2025 | |
| Hongbo Lu |
3/4/5
|
Director |
0.04%
|
52,012
|
$3,998,682 | -$228,334 | 12 May 2026 | |
| Douglas S. Ingram |
3/4/5
|
Director |
0.03%
|
46,215
|
$1,869,396 | — | 16 Dec 2025 | |
| Victoria Vakiener |
3/4/5
|
Director |
0.03%
|
35,723
|
$2,443,095 | -$679,491 | 19 Dec 2025 | |
| Adeoye Y. Olukotun |
3/4/5
|
Director |
0.02%
|
33,600
|
$2,300,928 | -$676,623 | 19 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3%
|
4,278,828
|
$274,501,765 | — | 31 Mar 2026 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
2.4%
|
3,342,493
|
$209,574,311 | — | 31 Mar 2026 | |
| Invesco Ltd. |
13F
|
Company |
2.3%
|
3,280,647
|
$205,696,568 | — | 31 Mar 2026 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.6%
|
2,275,000
|
$142,642,500 | — | 31 Mar 2026 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.4%
|
1,992,783
|
$124,947,494 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.2%
|
1,739,923
|
$109,093,172 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.2%
|
1,655,837
|
$103,820,980 | — | 31 Mar 2026 | |
| Siren, L.L.C. |
13F
|
Individual |
1.1%
|
1,615,476
|
$101,290,345 | — | 31 Mar 2026 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.1%
|
1,573,297
|
$98,645,722 | — | 31 Mar 2026 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1%
|
1,436,990
|
$90,119,095 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.95%
|
1,336,271
|
$83,784,191 | — | 31 Mar 2026 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.94%
|
1,330,996
|
$83,453,449 | — | 31 Mar 2026 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.9%
|
1,273,266
|
$79,612,179 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.84%
|
1,192,085
|
$74,743,730 | — | 31 Mar 2026 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.84%
|
1,190,335
|
$74,634,005 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.84%
|
1,183,838
|
$74,226,643 | — | 31 Mar 2026 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.79%
|
1,113,568
|
$69,820,712 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.75%
|
1,064,455
|
$66,741,328 | — | 31 Mar 2026 | |
| Hood River Capital Management LLC |
13F
|
Company |
0.75%
|
1,056,534
|
$66,244,682 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.74%
|
1,043,732
|
$65,443,000 | — | 31 Mar 2026 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.73%
|
1,036,495
|
$64,988,237 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.68%
|
965,775
|
$60,554,093 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.68%
|
960,507
|
$60,223,906 | — | 31 Mar 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.68%
|
960,144
|
$60,201,043 | — | 31 Mar 2026 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.59%
|
836,981
|
$52,478,709 | — | 31 Mar 2026 | |
| Western Financial Corp/CA |
13F
|
Company |
0.58%
|
820,239
|
$51,428,985 | — | 31 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.48%
|
683,068
|
$39,378,880 | — | 31 Mar 2026 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.46%
|
656,129
|
$41,139,289 | — | 31 Mar 2026 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.46%
|
651,544
|
$40,851,913 | — | 31 Mar 2026 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.46%
|
650,599
|
$40,792,557 | — | 31 Mar 2026 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.43%
|
608,531
|
$38,149,870 | — | 31 Mar 2026 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.42%
|
587,125
|
$36,812,738 | — | 31 Mar 2026 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
0.41%
|
585,682
|
$36,722,261 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for ARROWHEAD PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Hongbo Lu | ARWR | Common Stock | Sale | -5.4% | $228,334 | $76.88 | -2,970 | 52,012 | 12 May 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -4.22% | $750,000 | $75.00 | -10,000 | 226,958 | 23 Apr 2026 | Direct |
| Daniel Joseph Apel | ARWR | Common Stock | Sale | -7.44% | $934,285 | $71.35 | -13,095 | 162,905 | 22 Apr 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -4.05% | $641,900 | $64.19 | -10,000 | 236,958 | 05 Mar 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Award | 43.6% | 75,000 | 246,958 | 06 Jan 2026 | Direct | ||
| Daniel Joseph Apel | ARWR | Common Stock | Award | 74.1% | 75,000 | 176,200 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Award | 15.9% | 75,000 | 547,408 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Gift | -0.53% | -2,500 | 472,408 | 06 Jan 2026 | Direct | ||
| Patrick O'Brien | ARWR | Common Stock | Sale | -9.44% | $3,123,349 | $63.11 | -49,493 | 474,908 | 05 Jan 2026 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -18.9% | $2,534,661 | $63.11 | -40,164 | 171,958 | 05 Jan 2026 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.35% | $871,703 | $66.10 | -13,187 | 3,792,739 | 02 Jan 2026 | Direct |
| Patrick O'Brien | ARWR | Common Stock | Gift | -0.53% | -2,800 | 524,401 | 31 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -1.34% | $3,575,575 | $69.13 | -51,726 | 3,805,926 | 29 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Options Exercise | 1.36% | 51,726 | 3,857,652 | 29 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Stock Option (right to buy Common Stock) | Options Exercise | -100% | -51,726 | 0 | 29 Dec 2025 | Direct | ||
| Mauro Ferrari | ARWR | Common Stock | Sale | -9.83% | $527,100 | $70.00 | -7,530 | 69,053 | 26 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.33% | $861,340 | $68.44 | -12,586 | 3,805,926 | 22 Dec 2025 | Direct |
| William D. Waddill | ARWR | Common Stock | Sale | -12.9% | $566,038 | $67.65 | -8,367 | 56,563 | 19 Dec 2025 | Direct |
| Victoria Vakiener | ARWR | Common Stock | Sale | -21.9% | $679,491 | $67.68 | -10,040 | 35,723 | 19 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -0.35% | $909,683 | $67.66 | -13,445 | 3,818,512 | 19 Dec 2025 | Direct |
| Adeoye Y. Olukotun | ARWR | Common Stock | Sale | -22.9% | $676,623 | $67.66 | -10,000 | 33,600 | 19 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -2.17% | $5,443,462 | $64.04 | -85,000 | 3,831,957 | 17 Dec 2025 | Direct |
| Mauro Ferrari | ARWR | Common Stock | Award | 11.4% | 7,819 | 76,583 | 16 Dec 2025 | Direct | ||
| Hongbo Lu | ARWR | Common Stock | Award | 16.6% | 7,819 | 54,982 | 16 Dec 2025 | Direct | ||
| Michael S. Perry | ARWR | Common Stock | Award | 6.78% | 7,819 | 123,059 | 16 Dec 2025 | Direct | ||
| Victoria Vakiener | ARWR | Common Stock | Award | 20.6% | 7,819 | 45,763 | 16 Dec 2025 | Direct | ||
| Douglas S. Ingram | ARWR | Common Stock | Award | 20.4% | 7,819 | 46,215 | 16 Dec 2025 | Direct | ||
| Adeoye Y. Olukotun | ARWR | Common Stock | Award | 21.8% | 7,819 | 43,600 | 16 Dec 2025 | Direct | ||
| William D. Waddill | ARWR | Common Stock | Award | 13.7% | 7,819 | 64,930 | 16 Dec 2025 | Direct | ||
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -1.37% | $3,398,187 | $62.58 | -54,298 | 3,916,957 | 16 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Sale | -3.17% | $8,950,615 | $68.85 | -130,000 | 3,971,255 | 15 Dec 2025 | Direct |
| Christopher Richard Anzalone | ARWR | Common Stock | Award | 4.59% | 180,000 | 4,101,255 | 12 Dec 2025 | Direct | ||
| Michael S. Perry | ARWR | Common Stock | Sale | -12.4% | $991,738 | $61.03 | -16,250 | 115,240 | 05 Dec 2025 | Direct |
| Mauro Ferrari | ARWR | Common Stock | Sale | -11.3% | $493,412 | $56.39 | -8,750 | 68,764 | 28 Nov 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -8.62% | $700,000 | $35.00 | -20,000 | 212,122 | 01 Oct 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -6.07% | $450,000 | $30.00 | -15,000 | 232,122 | 12 Sep 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -5.72% | $375,000 | $25.00 | -15,000 | 247,122 | 02 Sep 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -3.46% | $187,780 | $20.00 | -9,389 | 262,122 | 15 Aug 2025 | Direct |
| James C. Hamilton | ARWR | Common Stock | Sale | -0.22% | $12,220 | $20.00 | -611 | 271,511 | 13 Aug 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.